Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys

ABSTRACT Three tetravalent vaccine (TV) formulations of previously described monovalent dengue (DEN) virus vaccine candidates were compared to a tetravalent formulation of wild-type DEN viruses (T-wt) for replication in SCID mice transplanted with human liver cells (SCID-HuH-7) or for replication and immunogenicity in rhesus monkeys. TV-1 consists of recombinant DEN1, -2, -3, and -4, each with a 30-nucleotide deletion in the 3′ untranslated region (Δ30). TV-2 consists of rDEN1Δ30, rDEN4Δ30, and two antigenic chimeric viruses, rDEN2/4Δ30 and rDEN3/4Δ30, both also bearing the Δ30 mutation. TV-3 consists of rDEN1Δ30, rDEN2Δ30, rDEN4Δ30, and a 10-fold higher dose of rDEN3/4Δ30. TV-1 and TV-2 were attenuated in SCID-HuH-7 mice with minimal interference in replication among the virus components. TV-1, -2, and -3 were attenuated in rhesus monkeys as measured by duration and peak of viremia. Each monkey immunized with TV-1 and TV-3 seroconverted to the four DEN components by day 28 with neutralization titers ranging from 1:52 to 1:273 and 1:59 to 1:144 for TV-1 and TV-3, respectively. TV-2 induced low antibody titers to DEN2 and DEN3, but a booster immunization after 4 months increased the neutralizing antibody titers to greater than 1:100 against each serotype and elicited broad neutralizing activity against 19 of 20 DEN subtypes. A single dose of TV-2 induced protection against wild-type DEN1, DEN3, and DEN4 challenge, but not DEN2. However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials.

[1]  D. Gubler,et al.  Epidemic dengue 3 in central Java, associated with low viremia in man. , 1981, The American journal of tropical medicine and hygiene.

[2]  R. Lanciotti,et al.  Molecular evolution and epidemiology of dengue-3 viruses. , 1994, The Journal of general virology.

[3]  Charles M. Rice,et al.  Flaviviridae :T he Viruses and Their Replication , 2007 .

[4]  P. Wehrle.  IMMUNIZATION AGAINST VIRAL DISEASES. , 1965, California medicine.

[5]  C. Huang,et al.  Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.

[6]  Arguments for live flavivirus vaccines , 2004, The Lancet.

[7]  D. Gubler,et al.  Dengue and dengue hemorrhagic fever. , 2014 .

[8]  R. Edelman,et al.  Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.

[9]  F. Guirakhoo,et al.  Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates , 2004, Journal of Virology.

[10]  J. Lang,et al.  Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children , 2004, The Pediatric infectious disease journal.

[11]  E. Holmes,et al.  Widespread intra-serotype recombination in natural populations of dengue virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Lanciotti,et al.  Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiological investigations. , 1992, Journal of virological methods.

[13]  B. Murphy,et al.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. , 2002, Virology.

[14]  B. Murphy,et al.  Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice , 2003, Archives of Virology.

[15]  B. Murphy,et al.  A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys , 2003, Journal of Virology.

[16]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[17]  D. Vaughn,et al.  Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. , 2003, The American journal of tropical medicine and hygiene.

[18]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[19]  B. Murphy,et al.  Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice , 2001, Journal of Virology.

[20]  D. Trent,et al.  Genetic relatedness among structural protein genes of dengue 1 virus strains. , 1989, The Journal of general virology.

[21]  A. Nisalak,et al.  Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. , 2002, The Journal of infectious diseases.

[22]  M. Guzmán,et al.  Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[23]  S. Halstead,et al.  Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. , 2002, Vaccine.

[24]  B. Murphy,et al.  Genetically modified, live attenuated dengue virus type 3 vaccine candidates. , 2004, The American journal of tropical medicine and hygiene.

[25]  R. Rico-Hesse.  Microevolution and virulence of dengue viruses. , 2003, Advances in virus research.

[26]  B. Murphy,et al.  Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes , 2002, Journal of Virology.

[27]  C. Huang,et al.  Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.

[28]  D. Gubler,et al.  Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. , 1978, The American journal of tropical medicine and hygiene.

[29]  B. Murphy,et al.  Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 , 2004, BMC infectious diseases.

[30]  A. Prata.  Yellow fever. , 2000, Memorias do Instituto Oswaldo Cruz.

[31]  E. Chungue,et al.  Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996–1997 dengue‐2 outbreak in French Polynesia , 2000, Journal of medical virology.

[32]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[33]  R. Lanciotti,et al.  Molecular evolution and phylogeny of dengue-4 viruses. , 1997, The Journal of general virology.

[34]  B. Murphy,et al.  Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. , 2004, Vaccine.

[35]  A. Sabin.  Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[36]  B. Murphy,et al.  Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. , 2003, Vaccine.

[37]  F. Murphy,et al.  Immunization against Viral Diseases , 1968 .

[38]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[39]  P. Wright,et al.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.

[40]  D. Gubler,et al.  Impact of dengue/dengue hemorrhagic fever on the developing world. , 1999, Advances in virus research.

[41]  J. Lang,et al.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. , 2002, The American journal of tropical medicine and hygiene.

[42]  D. Vaughn,et al.  Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.

[43]  B. Murphy,et al.  A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. , 2003, Virology.

[44]  G. Crane.  Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .

[45]  B. Murphy,et al.  Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. , 2003, Vaccine.

[46]  D. Vaughn,et al.  Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. , 2003, The American journal of tropical medicine and hygiene.

[47]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.